

**VANCOUVER GENERAL HOSPITAL
CSU PHARMACEUTICAL SCIENCES
SPECIAL ACCESS PROGRAM DRUG DATA SHEET**

DRUG NAME

Capreomycin

ALTERNATE NAMES

Capastat®

MANUFACTURER

Eli Lilly

STRENGTH

1g vials

DOSAGE FORM

injection

INDICATIONS

- In combination with other agents for treatment of susceptible strains of *M.tuberculosis*.
-

DOSAGE AND ADMINISTRATION

- 1g IV/IM daily (max 20mg/kg/day) for 60-120 days followed by 1g IV/IM 2 or 3 times per week for a total of 12-24 months of therapy.
 - Reconstitute each 1g capreomycin vial with sterile water or normal saline. For a 1g dose, reconstitute with 2mL and administer 2.7mL (entire withdrawable contents of the vial). For doses less than 1g, reconstitute each vial with 3.4mL, to yield 4mL of 260mg/mL solution.
 - For IV administration, dilute each 1g capreomycin vial in 100mL normal saline. Infuse over 60 minutes.
-

KNOWN SIDE EFFECTS*

- Most common adverse event is nephrotoxicity; the dose should be reduced or the drug discontinued if renal function deteriorates significantly.
 - Ototoxicity and vestibular toxicity — characterized by loss of hearing, ringing or buzzing or a feeling of fullness in the ears, dizziness and poor coordination.
 - Electrolyte disturbances including hypokalemia, hypocalcemia and hypomagnesemia.
 - Leukocytosis and leukopenia.
 - Urticaria, maculopapular skin rash and febrile reactions.
 - Muscular cramps, pain or weakness; dizziness and drowsiness
 - Elevation of LFTs
-

SPECIAL PRECAUTIONS

- Reconstituted vials and diluted IV bags are stable for 24hrs when refrigerated.
 - Renal function, serum electrolytes, and liver function must be monitored during therapy.
 - Audiometric testing and vestibular function should be assessed prior to and at regular intervals during therapy.
 - Avoid concomitant administration of other nephrotoxic and ototoxic drugs.
-

***REPORT ANY ADVERSE DRUG REACTIONS TO THE PHARMACY**